These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 12870120

  • 1. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.
    Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS.
    J Infect Dis; 2003 Aug 01; 188(3):388-96. PubMed ID: 12870120
    [Abstract] [Full Text] [Related]

  • 2. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team.
    Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 4. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
    Montes de Oca Arjona M, Pérez Cano R, Orozco MJ, Martín Aspas A, Guerrero F, Fernández Gutiérrez Del Alamo C, Girón-González JA.
    Clin Microbiol Infect; 2005 Jan 13; 11(1):57-62. PubMed ID: 15649305
    [Abstract] [Full Text] [Related]

  • 5. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.
    Clin Infect Dis; 2005 Mar 01; 40(5):728-34. PubMed ID: 15714420
    [Abstract] [Full Text] [Related]

  • 6. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN, Shang H, Jiang YJ, Liu J, Dai D, Diao YY, Geng WQ, Jin X, Wang YN.
    Chin Med J (Engl); 2006 Dec 05; 119(23):1966-71. PubMed ID: 17199940
    [Abstract] [Full Text] [Related]

  • 7. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 8. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.
    J Med Virol; 2004 Jul 13; 73(3):350-61. PubMed ID: 15170628
    [Abstract] [Full Text] [Related]

  • 9. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection.
    Powers AE, Marden SF, McConnell R, Leidy NK, Campbell CM, Soeken KL, Barker C, Davey RT, Dybul MR.
    AIDS; 2006 Apr 04; 20(6):837-45. PubMed ID: 16549967
    [Abstract] [Full Text] [Related]

  • 10. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 04; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 11. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
    Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, McNamara J, Hodge J, Hughes MD, Lindsey JC, Pediatric AIDS Clinical Trial Group 381 Study Team.
    J Infect Dis; 2004 Jul 15; 190(2):271-9. PubMed ID: 15216461
    [Abstract] [Full Text] [Related]

  • 12. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 13. Intermittent antiretroviral therapy in patients with controlled HIV infection.
    Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, May T, Ragnaud JM, Aboulker JP, Molina JM, ANRS 106 Study team.
    AIDS; 2007 Feb 19; 21(4):457-66. PubMed ID: 17301564
    [Abstract] [Full Text] [Related]

  • 14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM, López M, Lozano S, González-Lahoz J, Soriano V.
    J Infect Dis; 2008 Nov 15; 198(10):1466-73. PubMed ID: 18847371
    [Abstract] [Full Text] [Related]

  • 16. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N, Soria A, Galli L, Castagna A, Cernuschi M, Hasson H, Lazzarin A.
    J Med Virol; 2004 Feb 15; 72(2):181-6. PubMed ID: 14695657
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML, Rivas P, Molina M, Garcia R, De Górgolas M.
    Clin Infect Dis; 2005 Aug 01; 41(3):390-4. PubMed ID: 16007538
    [Abstract] [Full Text] [Related]

  • 18. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.
    Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, Badolato R, Giaquinto C, Lisi C, de Martino M, Italian Register for HIV Infection in Children.
    AIDS; 2006 Jan 09; 20(2):207-15. PubMed ID: 16511413
    [Abstract] [Full Text] [Related]

  • 19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.
    AIDS; 2008 Nov 12; 22(17):2371-80. PubMed ID: 18981777
    [Abstract] [Full Text] [Related]

  • 20. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA.
    Clin Infect Dis; 2005 Feb 15; 40(4):594-600. PubMed ID: 15712083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.